clindamycin hydrochloride

(redirected from Zindaclin)

clindamycin hydrochloride

Apo-Clindamycin (CA) Cleocin, Dalacin C

clindamycin palmitate hydrochloride

Cleocin Pediatric, Dalacin C Flavored Granules (CA)

clindamycin phosphate

Cleocin Phosphate, Cleocin T,Clindagel, ClindaMax, Clindesse,Clindets, Dalacin C Phosphate (CA),Dalacin T (CA) (UK), Evoclin, Zindaclin (UK)

Pharmacologic class: Lincosamide

Therapeutic class: Anti-infective

Pregnancy risk category B

FDA Box Warning

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Cleocin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile.

• Because Cleocin therapy has been associated with severe colitis that may be fatal, it should be reserved for serious infections for which less toxic antimicrobials are inappropriate. It shouldn't be used in patients with non-bacterial infections such as most upper respiratory tract infections.

C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality because these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has occurred more than 2 months after administration of antibacterial agents.

• If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.


Inhibits protein synthesis in susceptible bacteria at level of 50S ribosome, thereby inhibiting peptide bond formation and causing cell death


Aerosol foam: 1%

Capsules: 75 mg, 150 mg, 300 mg

Granules for oral suspension: 75 mg/5 ml

Injection: 150 mg base/ml

Topical: 1% gel, lotion, single-use applicators, solution, and suspension

Vaginal cream: 2%

Vaginal suppositories (ovules): 100 mg

Indications and dosages

Severe infections caused by sensitive organisms (such as Bacteroides fragilis, Clostridium perfringens, Fusobacterium, pneumococci, staphylococci, and streptococci)

Adults: 300 to 450 mg P.O. q 6 hours, or (for other than C. perfringens) 1.2 to 2.7 g/day I.M. or I.V. in two to four equally divided doses

Children: 16 to 20 mg/kg/day P.O. (hydrochloride) in three to four equally divided doses, or 13 to 25 mg/kg/day P.O. (palmitate hydrochloride) in three to four equally divided doses

Neonates younger than 1 month: 15 to 20 mg/kg/day I.M. or I.V. in three to four equally divided doses

Acute pelvic inflammatory disease

Adults: 900 mg I.V. q 8 hours (given with gentamicin)

Acne vulgaris

Adults and children older than age 12:

Apply a thin film of topical gel, lotion, or solution locally to affected area b.i.d.

Off-label uses

• Bacterial vaginosis (phosphate)

Chlamydia trachomatis infection in females

• CNS toxoplasmosis in AIDS patients (given with pyrimethamine)

Pneumocystis jiroveci pneumonia (given with primaquine)

• Rosacea (lotion)


• Hypersensitivity to drug or lincomycin


Use cautiously in:

• renal or hepatic impairment

• known alcohol intolerance

• pregnant patients

• neonates.


• Give oral doses with full glass of water, with or without food.

Don't give as I.V. bolus injection.

• Dilute I.V. solution to a concentration of 18 mg/ml using normal saline solution, dextrose 5% in water, or lactated Ringer's solution. Infuse no faster than 30 mg/minute.

• Don't administer I.M. dosages above 600 mg.

• Inject I.M. doses deep into large muscle mass to prevent induration and sterile abscess.

Adverse reactions

GI: nausea, vomiting, diarrhea, abdominal pain, esophagitis, pseudomembranous colitis

Hematologic: neutropenia, leukopenia, agranulocytosis, thrombocytopenia purpura

Hepatic: jaundice, hepatic dysfunction

Skin: maculopapular rash, generalized morbilliform-like rash

Other: bitter taste (with I.V. use), phlebitis at I.V. site, induration and sterile abscess (with I.M. use), anaphylaxis


Drug-drug. Erythromycin: antagonistic effect

Kaolin/pectin: decreased GI absorption of clindamycin

Hormonal contraceptives: decreased contraceptive efficacy

Neuromuscular blockers: enhanced neuromuscular blockade

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatine kinase: increased levels

Platelets, white blood cells: transient decrease in counts

Patient monitoring

• Monitor creatinine level closely in patients with renal insufficiency.

• Monitor hepatic enzyme levels in patients with hepatic disease.

• Assess for signs and symptoms of hypersensitivity reactions, including anaphylaxis.

• Assess for diarrhea and signs and symptoms of colitis.

Patient teaching

• Tell patient to take drug with food if it causes stomach upset.

Urge patient to contact prescriber immediately if he develops rash, unusual fatigue, or yellowing of skin or eyes or if diarrhea occurs during or after treatment.

• Tell patient that I.V. use may cause bitter taste. Reassure him that this effect will resolve on its own.

• Caution patient not to rely on condoms or diaphragm for contraception for 72 hours after using vaginal preparation; drug may weaken latex products and cause breakage.

• Instruct patient taking hormonal contraceptives to use supplemental birth control method, such as condoms (unless she's using a vaginal preparation); drug may reduce hormonal contraceptive efficacy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved

clindamycin hydrochloride

An antibiotic drug that treats infections with gram-positive and anaerobic organisms. Like other antibiotics, it may alter the flora of the gastrointestinal tract, leading to pseudomembranous colitis caused by overgrowth of Clostridium difficile.
Medical Dictionary, © 2009 Farlex and Partners
Mentioned in ?
References in periodicals archive ?
DRUG company ProStrakan Group yesterday sold their acne gel Zindaclin to Crawford Healthcare.
Zindaclin was the first product Galashiels firm ProStrakan developed and was launched in the UK in 2002.
Zindaclin, a unique, once-a-day clindamycin-based gel for the treatment of acne, has been in-licensed from UK based Strakan Pharmaceuticals.
The size of the anti-acne market in Australia for Zindaclin is estimated to be worth approximately A$12 million.
A new treatment has just become available on prescription (Zindaclin) which only has to be applied to the skin once a day (rather than twice as with existing creams and lotions) and this may be more helpful for teenagers.